News
CAR T-cell Clinical Trial Shows Promise, Advances to Next Dose Level
The world’s first clinical trial for CAR T-cell therapy in neuroendocrine tumors has advanced to a higher dose level, an indication of progress. Advancing to
When Watching Isn’t Enough: Somatostatin Analogs Show Promise in Small Pancreatic NETs
By Anna Greene, PhD, NETRF Director of Research For many patients newly diagnosed with small, nonfunctioning pancreatic neuroendocrine tumors (PanNETs), active surveillance (AS) with regular
Reimagining the Final Chapter: The Critical Role of Palliative Care in Neuroendocrine Tumors
By Anna Greene, PhD, NETRF Director of Research A recent study by Suriya Baskar, MD, and Udhayvir Singh Grewal, MD, published in the Journal of
Clinical Trial for NET Treatment Moves to Higher Dose Testing
Perspective Therapeutics has begun enrolling participants into the next phase of its clinical trial of a new targeted alpha radiation therapy for neuroendocrine tumors (NETs).
Living My Neuroendocrine Cancer Journey Out Loud
“Where do you see yourself in five years?” I’ve stopped answering that question. Five years ago I was 31. Five years ago I was planning my wedding. Five
Welcoming Brilliant Minds: NETRF’s Board of Scientific Advisors Grows Stronger
At the Neuroendocrine Tumor Research Foundation (NETRF), we believe that the path to better treatments and cures, starts with research. However, ensuring that we fund
How NIH Cuts Are Threatening the Future of Neuroendocrine Cancer Research
By Anna Greene, PhD, NETRF Director of Research The landscape of biomedical research is undergoing a seismic shift. This year alone, the NIH has awarded
Update on 2025 NETRF Grant Cycle
At NETRF, our annual Request for Applications (RFA) is a cornerstone of our mission to fund innovative research in neuroendocrine cancer. This two-stage process is
Beyond Size: Rethinking How We Manage Small Pancreatic Neuroendocrine Tumors
By Anna Greene, PhD, Director of Research, NETRF Pancreatic neuroendocrine tumors (PanNETs) are a rare but increasingly detected cancer, thanks in part to more widespread
New Study Sheds Light on the Hidden Genetics of Metastatic Neuroendocrine Cancer
By Anna Greene, PhD, NETRF Director of Research Unlocking the Molecular Mysteries of Neuroendocrine Neoplasms (NENs) A study published this month by NETRF-funded Collaborative Grant